Orient Bell turns around: consolidated PAT ₹8.32 Cr in Q1FY27 vs loss YoY, OPM up to ~8%
revenue +42.49% · margins expanding
₹203.62 Cr
+42.49% YoY
₹8.32 Cr
4.06%
+4.3pp YoY
₹5.66
Orient Bell's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue came in at ₹203.62 Cr, up 42.5% year-on-year from ₹142.90 Cr in Q1 FY26 — a period when the company posted a net loss of ₹0.37 Cr. This quarter the company turned profitable with consolidated PAT of ₹8.32 Cr (EPS ₹5.66 basic), a clean swing from loss to profit with no exceptional items on either side of the comparison (Q4 FY26 alone carried a ₹1.29 Cr one-off, absent here). Sequentially, revenue eased 5.1% from Q4 FY26's ₹214.64 Cr — expected given Q4 is typically the stronger quarter for tile demand tied to year-end construction activity — while PAT still grew 33.7% QoQ from ₹6.22 Cr, pointing to margin gains carrying through even as volumes normalized.
Q1 FY-2027 vs prior quarters
Margins expanded sharply: consolidated NPM moved to 4.09% from -0.26% a year ago, and operating margin to roughly 8.1% from about 3.5% YoY (and ~6.1% in Q4 FY26). The bridge sits mostly on the expense mix — purchases of traded stock-in-trade fell to 21.0% of revenue from 28.5% a year ago and employee costs eased to 14.7% of revenue from 17.3%, both signs of better operating leverage and a shift toward own manufacturing over bought-out goods. Partly offsetting this, power & fuel costs rose to 24.9% of revenue from 19.9% YoY, an inflationary drag the company absorbed within the overall expansion.
The stock went into the print at ₹348, up 8.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 4 consecutive quarters.
Management expressed confidence in sustained margin performance driven by pricing actions and operational efficiencies. While not providing specific revenue growth guidance for FY27, they indicated optimism for the year based on past performance and ongoing strategic initiatives. The company is focused on continuing it
— This quarter: met
Standalone tracked closely with consolidated — PAT of ₹8.43 Cr on revenue of ₹200.96 Cr, EPS ₹5.73 — with no material divergence between the two bases. Management's Q4 FY26 call had flagged confidence in sustained margin performance from pricing actions and operational efficiencies, without specific FY27 revenue growth guidance; this quarter's OPM and NPM expansion is consistent with that framing, so the guidance reads on-track. No street consensus estimates for this specific quarter could be sourced, so the print cannot be benchmarked against analyst expectations. The results were approved alongside the company's 49th AGM held the same day (August 11, 2026), and follow the July 15 announcement extending CEO Aditya Gupta's tenure by five years — management continuity through this margin-recovery phase.
W1
Power & fuel cost ratio (24.9% of revenue in Q1FY27, up from 19.9% YoY) — whether this inflationary drag stabilizes or keeps eating into margin gains
W2
FY27 revenue growth pace — management gave no specific guidance; the 42.5% YoY print partly reflects a soft Q1FY26 base, watch if growth holds through Q2
W3
Sequential trend into Q2 FY27 given Q4 FY26 was seasonally stronger (revenue -5.1% QoQ) — confirm operating leverage holds as volumes normalize
Clear tabular statement, unaudited (limited review). Consolidated PBT includes a ₹0.26 Cr share of associates' loss; no exceptional items this quarter (Q4 FY26 alone had a ₹1.29 Cr one-off). All figures converted from ₹ Lakh (÷100).
₹8,450 Crore Order Book Meets a ₹9.4% Margin
Alicon delivered record revenue (+38% YoY) and an order book worth ₹8,450 crore over six years. The street marked it down 2.95% on day 1 anyway. The gap between the order pipeline and the margin squeeze is where the real risk lives.
₹578 Cr
+38.3% YoY, +16.8% QoQ; real volume growth +17.5% (ex-aluminum)
9.4%
vs 11–12% prior; compressed despite cost recovery claims
₹11.4 Cr
+29.8% YoY; NPM 2.0% (lag vs revenue growth suggests tax/D&A burden)
₹8,450 Cr
6-year executable; ₹450 Cr + ₹850 Cr booked Q1
The quarter presents a classic earnings illusion. Revenue hit a record ₹578 crore (+38.3% YoY), and management raised FY27 growth guidance to 12–15% volume-adjusted. But the street marked it down 2.95% on day 1 anyway. Why? Because profit growth (+29.8% PAT) lagged revenue growth (+38.3%), operating margins compressed to 9.4% from 11–12%, and the real story sits between the headline and the guidance: Alicon is growing volume aggressively in a strong market, but structural margin improvement remains unproven. The ₹8,450-crore order book is material and real. The question is whether execution on complex programs and cost recovery will turn it into returns.
The margin squeeze: inflation vs. recovery
Reported revenue of ₹578 crore includes aluminum pass-through at list price: inflation-adjusted real volume growth was 17.5%, solid but not exceptional. Operating profit landed at 9.4%, down sharply from 11–12% in prior quarters. Management's narrative: aluminum is fully hedged at real-time pricing (effective April 1); labor and energy cost recovery is 'progressing in customer discussions,' with 'some approvals secured, others in flight.' The forensics of Q1 suggest the lag is real. Adjusted OPM, excluding aluminum, was roughly 11.4%—essentially flat YoY despite value-addition growth of +17.6%. That's not margin expansion; it's margin defense while inflation is being absorbed on both sides of the invoice.
We cannot simply rely on the price increases to protect the margins. We have to become structurally more efficient.
This statement—not the order book, not the guidance—is the quarter's honest note. Management is telegraphing that pricing power is limited and that profitability is contingent on operational discipline and mix-shift. That's a meaningful pullback from any aspiration of achieving the prior 14–15% EBITDA-margin target on pricing alone.
Real growth 17.5% after adjusting material inflation
Revenue +38.3% reported; aluminum accounts for ~20pp; 17.5% underlying volume growth is supported by tonnage data (9,124 tons +1% YoY) and mix-shift drivers (PV, hybrid, complex parts).
Supported
Strong profitability growth despite input cost volatility
PAT +29.8% YoY is healthy in isolation. But OPM compressed to 9.4% from 11–12%, and adjusted OPM (ex-aluminum) is flat YoY at ~11.4%. NPM 2.0% vs 9.5% EBITDA indicates ₹7+ crore in tax/D&A/working-capital drag not addressed.
Overstated
Order book ₹8,450 Cr executable with clear program visibility
Recent wins ₹450 Cr (5-yr, mixed programs) + ₹850 Cr (2 large OEMs, 5-yr) are real and booked. Over 6 years, ~₹1.4K crore in new-order revenue is annualized. But visibility and execution credibility are distinct.
Supported in aggregate; execution risk material
JLR e-Axle program ramping toward 600 sets/week with significant margin upside
JLR currently marginal in Q1 (600 sets/wk is the production target by Q3 calendar). SOP was delayed due to 2–3 year development cycles (vs 6–12 month standard); this compressed margins and delayed returns on earlier capex. When JLR peaks Q3, Q4 could show accretion, but timing is uncertain.
Supported in future; credibility gap in present
European recovery from Q4 FY27 onward; new programs under development
Currently 150–200 tons (~2% consolidated). Legacy programs ended Q1. New e-Axle program from large OEM is SOP Q4 FY27 (expected). This is a recovery assumption, not a near-term driver. Prior European guidance (Q2–Q3 recovery) materially missed.
Partial; timing risk high
Non-automotive diversification (HVAC, tractor, defence) building scale by end FY27
Non-auto is currently 2% of order book, down from a 25% prior aspiration. Team hired 7–8 months ago; early wins (HVAC data center, tractor, defence RFQs) exist. CEO expects 'positive change by end of FY27' but acknowledged it won't reach aspiration targets.
Hedged; scale unproven
What changed on this call
FY27 volume growth guidance raised to 12–15% (from prior 8–10%)
Large customer wins booked: ₹450 Cr + ₹850 Cr (strategic shift to PV/CV complexity)
Non-auto aspiration downgraded to 2% order book (from 25% revenue target)
European recovery timeline extended to Q4 FY27 (vs prior Q2–Q3)
Margin guidance conservatized: 'at least 1% improvement' (vs prior 1.5% aspiration)
Strategy reframed as ICE/hybrid focus (faster cycles) vs EV (2–3 year development)
The bull-bear ledger
Record revenue and executable order book (₹8,450 Cr over 6 years) anchor structural growth
Hybrid moat: single-source supplier to India's largest hybrid OEM (1M cylinders/year)
Market tailwinds strong: PV +11.3% Q1, hybrid +25–30% CAGR, CV +19.5%
Capacity >90% full; order-backed capex (Shikrapur ₹125 Cr → ₹500 Cr revenue, 4–5 years)
Reported profit lagged revenue growth (+29.8% vs +38.3%); margin compression visible and material
Operating margin 9.4% vs 11–12% prior; cost recovery only partial, timeline uncertain
ROCE structurally low at 10.7%; capex payback 3–4 years; if ROI disappoints, returns stay below WACC
Execution track record mixed: EV delays 2–3 years (vs 6–12 months standard), non-auto aspiration collapsed 25% → 2%
JLR marginal in Q1 despite 2–3 year development; European programs soft; timing risk material
Margin aspiration 14–15% with no timeline; credibility strained by Q1 compression and prior guidance misses
How the street is positioned
The day-1 reaction: Alicon announced Q1 results with a pre-result close of ₹741.35. The stock fell 2.95% the following day (down to ~₹719), with delivery of 63.2% — a modest but meaningful selloff that suggests the street saw the headline revenue but discounted the margin story. This is not a 'beat and pop' result; it's a 'beat on volume, miss on profitability quality' reaction. The day-1 move reflects justified skepticism: order book is real, but margin bridge is unproven.
Valuation and drawdown: At ₹725.1 (as of 2026-08-17), Alicon is trading -29.05% off its all-time high of ₹1,022 and +25.02% off its 52-week low of ₹580. The stock sits below its 200-day SMA of ₹738.33 but above its 20-day and 50-day SMAs (₹697.09, ₹665.83), suggesting a consolidation phase after a significant sell-off. The ATH-to-now drop of nearly 30% is steep; it likely reflects both market-wide correction and company-specific skepticism about margin durability.
Ownership and flows: FII holding is minimal at 0.20%, unchanged QoQ. DII trimmed 91 basis points QoQ to 10.62% — a modest but notable reduction, suggesting institutional lightness. Promoter stake remains stable at 53.79% (-22 bps QoQ, de minimis). This is a promoter-controlled, retail-heavy stock with minimal institutional conviction. The DII trim into a quarter of strong volume growth is telling: large domestic institutions are not convinced by the order book without proof of margin recovery.
The street's implicit thesis: The market is pricing in execution risk (JLR, Shikrapur, European ramp) + margin-recovery uncertainty at a significant discount to order-book optionality. If Alicon could credibly demonstrate that the Q1 margin squeeze is temporary and Q2–Q3 brings cost-recovery approvals + JLR ramp, the stock likely re-rates higher. But the day-1 selloff into volume-growth headlines and the DII trim into strength suggest the street is not yet convinced. The next catalyst is Q2 cost recovery and Q3 JLR inflection data.
The debate
The honest read: Alicon is capturing market share in a strong cycle (PV +11%, hybrid +25–30% CAGR) with a credible, booked order pipeline (₹8,450 crore). Volume discipline is evident: Q1 real growth of +17.5% ex-inflation is good execution. But structural margin improvement is unproven. Q1 margin compression (9.4% from 11–12%) and profit-growth lag (29.8% PAT vs 38.3% revenue) are red flags that cost recovery and pricing discipline are weaker than the 'reset-refocus' narrative suggests. The capex story (Shikrapur, automation) is real, but ROI is unproven: ROCE remains 10.7% and the target of 15% is aspirational. The stock's -29% drawdown from ATH and the day-1 -2.95% selloff into volume headlines are justified: this is optionality priced, not returns priced. Execution, not order pipeline, will determine re-rating. Near-term catalysts (Q2 cost recovery, Q3 JLR ramp, Shikrapur SOP March 2027) are the tests.
Margin recovery unproven; cost-recovery lag compounds
HighQ1 OPM 9.4% vs 11–12% prior; adjusted OPM (ex-aluminum) flat YoY at ~11.4%. If labor/energy customer approvals slip, margin aspiration (14–15%) becomes unachievable. Equity thesis depends entirely on mix-shift + automation delivering incremental margin; neither is yet visible.
Program SOP delays and development burn
HighJLR e-Axle took 2–3 years development (vs 6–12 months standard), is still marginal Q1, and is ramping Q3. European programs under development (SOP Q4 FY27). Tractor and HVAC are first-time wins. Each SOP delay or miss compresses capex ROI and delays ROCE recovery. Development burn of ₹3–5 crore/quarter masks underlying operational efficiency.
ROCE structural pressure; capex ROI unproven
MediumPrior ROCE 10.7% vs cost of capital; target 15% requires mix-shift + automation. If capex on Shikrapur, automation, or European expansion fails to drive ROI, returns stay below WACC. Payback periods of 3–4 years are long; margin compression extends payback further.
Competitive foundry capacity +3x in India
MediumAluminum casting capacity expansion and commodity 2-wheeler casting shift margin risk. Alicon's shift to complex/machined products (PV, hybrid, EV, e-Axle) is defensive, but tech moat may erode as competitors develop capabilities. Pricing power in 2-wheeler already collapsed; 4-wheeler/hybrid may follow if competitive intensity rises.
European operations underutilized; recovery timing uncertain
MediumCurrently 150–200 tons (~2% consolidated). Legacy programs ended Q1. New programs SOP Q4 FY27 expected but timing is uncertain. Capacity drag on consolidated margin until utilization improves. Prior European guidance (Q2–Q3 recovery) was materially missed; credibility gap remains.
Non-automotive diversification fails to scale
LowNon-auto 2% of order book vs 25% prior aspiration. Team hired 7–8 months ago; expecting 'positive change by end FY27' but far short of targets. If scale remains low, company stays 98% automotive-exposed. Reduces earnings resilience in a downturn.
Prior guidance misses erode management credibility
LowEV program delays (2–3 years), non-auto failure (25% → 2%), European misses (Q2–Q3 recovery → Q4). Management acknowledged these but defended with 'industry-norm' timelines. Each miss increases market skepticism about margin aspirations and capex payback claims.
1 · Q2 cost-recovery approvals and margin trajectory
The key test. Has labor/energy cost recovery closed with customers? Is OPM recovering toward 11–12%, or stuck at 9–10%? If stuck, the margin-recovery thesis deteriorates and price target needs to reset lower. If recovering, the Q3 JLR ramp becomes the next inflection. Watch the CFO's commentary on 'approvals in flight' and expected timing.
2 · Q3 JLR production ramp and margin data
JLR entering peak production (600 sets/week target, calendar Q3 = FY27 Q3). If JLR is high-margin (it should be, complex product for UK OEM), Q3 could show meaningful EBITDA accretion and re-rate sentiment. Conversely, if ramp is delayed or margins are lower than expected, ROCE recovery hypothesis fails. Watch for production volumes, delivery rates, and margin commentary.
3 · Shikrapur facility SOP (March 2027 target)
All capacity pre-booked; if on-time, validates execution track record on schedule and unblocks capex ROI narrative. Delay would be a major red flag (credibility hit, ROCE pressure). Watch announcement of possession (Sept 2026 target) and tooling/trial-run updates. Any hint of pushout should reset expectations.
4 · Non-auto scale by end FY27
Management promised 'positive change' in the non-auto pie by end FY27. Currently 2% of order book. If it stays <5%, the aspiration is quietly abandoned and the growth story is 98% automotive (concentration risk). If it reaches 5–10%, it begins to look like a real third pillar. Watch Q3 and Q4 non-auto order announcements and revenue contribution.
5 · FY28 capex announcement (location, timing, ROI)
For ₹1,600 crore revenue by 2030 target (2x from ~₹800 crore base), Alicon needs >₹150 crore/year capex beyond Shikrapur. CEO hinted 'very soon' but withheld details ('different part of country', no location/timeline). Timing and ROI clarity will reset valuation. Watch for press release or next earnings call. Vague or delayed disclosure suggests confidence issues internally.
Alicon proved in Q1 that it can execute volume in a strong market. Revenue hit ₹578 crore (record), real growth was +17.5% ex-inflation, and the ₹8,450-crore, six-year order book is material and executable. But the quarter also confirmed that structural margin expansion is harder than the 'reset-refocus-rebuild' narrative suggests. Operating margins compressed to 9.4% (from 11–12%), profit growth lagged revenue growth, and cost recovery is only partial. The street's -2.95% day-1 reaction and -29% drawdown from ATH reflect justified skepticism: this is an optionality story (order book, capex, program ramps) priced at a discount to demonstrated returns (margin improvement, ROCE recovery).
The stock trades at ₹725 with RSI 61 (neutral), above near-term SMAs but below the 200-day. Institutional ownership is light (FII 0.20%, DII 10.62% and trimming). The bull case depends entirely on execution: Q2 cost recovery, Q3 JLR ramp, Shikrapur SOP by March 2027, and European recovery by Q4. If these inflections land on time and drive margin accretion, re-rating to ₹900–₹1,000 is plausible. If they slip, the order book becomes inventory of optionality without return, and the stock re-tests ₹600. For now, it's a Hold at ₹725. Watch Q2 for cost-recovery data and Q3 for JLR. The number to track from here is operating margin — not the order book, but whether Alicon can turn ₹8,450 crore in orders into sustainable profitability on the income statement.
Strong Q1 execution amid Morbi recovery headwind
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade A
Management executing on FY26 guidance (margin expansion, demand generation working). Met or beat expectations.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered strong 42.6% revenue growth and margin expansion (EBITDA 8.7%, +480 bps) via pricing power, demand initiatives (40% sellout vs 26% prior year), and premiumization. However, ~50% of volume growth came from temporary Morbi supply gap (now recovering), and pricing is dependent on gas volatility (INR60-62 currently, up from INR44-45). No FY27 guidance given despite optimistic tone, and geopolitical risks to exports visible.
₹203.8 Cr
Revenue · +42.6% YoY₹8.3 Cr
Reported PAT · +2319.6% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue ₹203 Cr, 42.8% YoY growth
METDelivered ₹203.8 Cr, +42.6% YoY; 22.9% volume + 15.9% ASP = 42.8% calc matches
Highest ever gross margin 39.7%
UnverifiedOPM 8.1%, NPM 4.1%—gross margin not separately disclosed in delivered results
EBITDA ₹17.6 Cr, 8.7% margin, 480 bps expansion
MET17.6/203.8 = 8.6% margin; prior year EBITDA margin ~1.7% implies 480 bps expansion supported
PBT ₹11.2 Cr (vs ₹-0.6 Cr loss prior year)
METDelivered PAT ₹8.3 Cr; PBT ~11.2 with ~25% tax rate reconciles
23% volume growth driven by demand generation + Morbi supply gap
MET22.9% volume growth claimed; mgmt split: (1) Morbi shutdown Apr-May (temporary), (2) demand initiatives—40% sellout vs 26% prior year (structural)
Price increase 18-19% vs pre-war, largely captured
METASP +15.9% as reported; gas INR44-45 pre-war → INR60-62 current matches magnitude; pricing held but sustainability tied to gas volatility
Earnings quality
What changed since the last call
Pricing power maintained despite competition
UpgradePrice gap vs Morbi narrowed from ₹100 to ₹50-55, but OBL still holding 18-19% increases. Organized player advantage real vs unorganized. Mgmt confidence on pricing backed by 40% sellout.
Demand generation traction visible
Upgrade40% sellout vs 26% prior year is structural improvement (not Morbi-driven). Drishti AI answering 10k Q's/month; dealers now confident on volume absorption. Digital initiatives shifting from cost to revenue driver.
Morbi dependence no longer existential
UpgradeOrganized players like OBL benefited from Morbi shutdown Apr-May. Dealers diversifying suppliers post-shutdown to reduce concentration risk. Structural shift favors branded, multi-location producers.
Capacity utilization trajectory positive
Upgrade73% vs 64% Q4 vs 60% FY26. Headroom to grow without incremental CapEx. GVT conversion (INR10 Cr) will further improve product mix and utilization.
Export opportunity disappeared
DowngradeIndustry exports ₹800 Cr/month avg (Apr-May) vs ₹1500-1600 Cr prior. Freight costs 5-6x up; West Asia demand down. Not direct OBL issue (low export exposure) but signals macro headwind, limits upside.
The Q&A
Q&A was substantive but probing. Analysts asked specifically on (1) Morbi situation and supply timing (pressed on plant shutdowns, labor issues), (2) pricing sustainability (gas volatility scenario), (3) volume growth drivers (demand vs supply gap), (4) capex deployment (INR60+ Cr cash). Management mostly answered directly; deflected on Dora plant-level utilization (said product mix more meaningful than plant metrics) but gave South/West market proxies (37-60% growth). No obvious evasion; some clarification requests but engaged overall.
Pricing & cost pass-through — Gunit Singh, Counter Cyclical PMS
Answered18-19% price hike vs pre-war. Currently no price cuts; watching volatility. Gas INR60 avg Q1, currently 1-2 rupee fluctuation. Will follow market.
Volume growth sustainability — Gunit Singh, Counter Cyclical PMS
AnsweredTwo drivers: (1) Morbi supply gap Apr-May (temporary), (2) demand initiatives—40% sellout vs 26%, dealers now confident on absorption. Optimistic on growth KPIs.
Morbi supply status — Gunit Singh, Counter Cyclical PMS
AnsweredPlants shut end-Mar to mid-May; now at capacity. Price gap narrowed from ₹100 to ₹50-55; positive for organized players. Dealers diversifying suppliers for security.
Dora plant utilization — Ashvath Rajan, Arihant Capital
PartialPlant-level utilization misleading (product mix changes by quarter). Instead: South market (Dora-focused) grew 37% in Q1 retail; West grew 60%. Better metric.
GVT product mix — Ashvath Rajan, Arihant Capital
Answered47% of sales by value is GVT. 15-20% from Dora, bulk from SKD, 4-5% from Morbi sourcing.
Blended capacity utilization — Ashvath Rajan, Arihant Capital
AnsweredFY26 blended 60%, Q1 now 73%. Headroom to grow; converting ceramic line to GVT will further help Q3/Q4.
Project vs retail split — Ashvath Rajan, Arihant Capital
AnsweredQ1 project revenue 18% (3000m+ definition). Grown faster in retail last few quarters; focusing on enterprise (large builder) growth now. No target %; both channels priority.
Gas cost drag in Q2 — Ashvath Rajan, Arihant Capital
AnsweredBulk of price increases happened in Q1. Now stable (INR1-2 variance). July prices close to Q1. But geopolitical risks (Iran, Russia refineries) make future uncertain.
Regional gas pricing — Apurva Sharma, Raas Capital
AnsweredSikandrabad pre-war INR44-45, now INR60-62 (formula-based on Brent rate, then spot). Morbi INR42-44 to INR69. So far holding prices; watching market.
Export opportunity — Sagar Jagtap, Marine Research
AnsweredExports down to ₹800 Cr/month avg (Apr-May) vs ₹1500-1600 pre-war. Freight costs 5-6x; West Asia demand weak. Market continues down.
FY27 guidance — Saurabh Jain, Sequent Investments
AnsweredAs a policy, we do not provide guidance for future. Encouraged by sales momentum; KPIs showing positive; hopeful year will perform better, no specific numbers.
Cash deployment — Ashvath Rajan, Arihant Capital
PartialINR15 Cr on near-term CapEx (ceramic-to-GVT conversion, digital printing, polishing). Larger portion for next growth phase; debating options, will announce in 2-3 months.
Tile adhesives strategy — Ashvath Rajan, Arihant Capital
AnsweredQ1 revenue ₹2.5 Cr; cash-and-carry model. Scaling geographies (North started, now expanding to North India + East). Small scale now; no plant CapEx; building quarter-on-quarter.
Guidance
No FY27 specific revenue guidance provided
LowManagement cites macro volatility (Middle East geopolitics, gas prices, export weakness). Optimistic on momentum but no targets.
No FY27 specific margin guidance provided; confident on pricing sustainability
MediumPricing 18-19% held so far; watching gas market. EBITDA margin at 8.7% Q1; management optimistic but not committing to level.
INR10 Cr ceramic-to-GVT conversion; INR15 Cr near-term CapEx; INR60+ Cr cash deployment pending
HighCeramic-to-GVT conversion underway Q3/Q4 FY27. Digital printing, polishing machine additions. Larger growth capex to be decided in 2-3 months.
Risks the call surfaced
Morbi supply recovery
HighQ1 benefited from Apr-May Morbi shutdown (production halted end-Mar to mid-May). ~50% of 23% volume growth from this temporary gap. Once Morbi fully online, volume growth moderates.
Pricing power erosion
High18-19% price increase partially offset input cost inflation (gas INR44-45 → INR60-62). If gas falls materially (20%+ drop), pricing power tested; management may need to cut prices to stay competitive.
Export market collapse
MediumIndustry exports down to ₹800 Cr/month (Apr-May) vs ₹1500-1600 Cr pre-war. Freight costs 5-6x up; West Asia demand weak. OBL not export-heavy, but shows macro softening.
Geopolitical supply chain volatility
MediumRussia refineries destroyed per management; lost ~1/3 capacity. Iran tensions ongoing. Could cascade into higher global gas prices; OBL vulnerable given GAIL contract dependence.
Competitive price pressure from Morbi
MediumGap between OBL and Morbi prices narrowed from ₹100 to ₹50-55. Continued narrowing would erode OBL's quality/brand premium and margin advantage.
Management
Score 7/10. Clear, transparent. Separated temporary (Morbi) from structural (demand gen) drivers. Acknowledged volatility and risks. Declined to give guidance due to macro uncertainty (prudent). Strong Q1 delivery on FY26 strategic priorities (margin expansion via pricing, demand generation working—40% sellout vs 26% prior, digital initiatives traction). Met/beat expectations.
1 · Q2 FY27 (Sep 2026)
Morbi supply normalization; volume growth deceleration expected; pricing under pressure
2 · H2 FY27 (Oct-Mar 2027)
Ceramic-to-GVT conversion (INR10 Cr capex) completion; capacity headroom grows
3 · Q3/Q4 FY27
South/West market expansion (currently +37-60% growth) continues; tile adhesives scale-up (started ₹2.5 Cr Q1)
No FY27 guidance given despite optimistic tone, and geopolitical risks to exports visible.